News & AnalysisNeuro23 takes in $100m Series CNeuron23 Inc., a developer of precision medicines, has secured $100 million in Series C financing.ByIris Dorbian30 March 2022•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs